Tagged with Strategy,

Saudi Arabia Recently appointed CEO of Saudi Chemical Company Holding’s Pharma Sector, Ismail Shehada is today drawing on 20+ years of Big Pharma experience to drive SCCH’s growing life sciences footprint in alignment with the Kingdom of Saudi Arabia’s Vision 2030 healthcare transformation. Shehada explains how SCCH is moving into third-party logistics…

Switzerland Barbara Fritsche-Surchat outlines Servier’s historic commitment to Switzerland, how the French mid-cap’s global oncology pivot is translating into its Swiss operations, and comments on the evolution of pharma salesforces post-pandemic.   Over the years, we have developed a real expertise, predominantly in the cardiovascular field, but we will leverage this…

Saudi Arabia Aspen’s regional CEO for the Middle East, North Africa & Turkey, Daniel Vella Friggieri, provides insights into how the South African company’s federated model and decentralized management system translates into differentiated portfolios across regions and significant networks of local CMO partners. After more than five years with Aspen in the…

Turkey Ercin Kugu, CSL Behring’s general manager for Turkey and Israel, highlights the rare disease company’s footprint in Turkey, explains the different regulatory framework in the country for plasma products, and provides insights on the process of establishing Big Pharma affiliates in Turkey from zero after doing so for both Shire…

Denmark Danish pharma industry veteran Peter Drøidal highlights how he steered the Danish Novartis affiliate through the COVID-19 pandemic period, the strategy in place to navigate an increasingly challenging market access landscape, and the lessons that can be leveraged from the value-based agreement that Novartis was able to strike with the…

Turkey After being present in the Turkish market for more than 28 years, MSD seems confident that it will be able to seize upcoming opportunities due to the country’s high prevalence of chronic disease, strong national immunization program and increasing life expectancy. Its general manager for the Turkey cluster, Gözde Güllüoğlu,…

APAC Francis Van Parys, vice president commercial Asia-Pacific at Cytiva, a global life sciences leader dedicated to advancing and accelerating therapeutics, highlights the firm’s tireless work to meet the exponential demand for the research, development, and manufacturing of therapies and vaccines against COVID-19. Van Parys also outlines the opportunities and challenges…

APAC Francis Van Parys, vice president commercial Asia-Pacific at Cytiva, a global life sciences leader dedicated to advancing and accelerating therapeutics, highlights the firm’s tireless work to meet the exponential demand for the research, development, and manufacturing of therapies and vaccines against COVID-19. Van Parys also outlines the opportunities and challenges…

Saudi Arabia Kamel Ghammachi and Karim Smaira are the co-founders of Genpharm, an entrepreneurial success story that now provides market access and marketing solutions for rare disease products across the MENA region. They discuss the impact of COVID-19 on their business; the evolving dynamics of the Saudi pharma market; and the crucial…

Denmark Speaking exclusively to PharmaBoardroom, Lundbeck’s global CEO Deborah Dunsire describes the progress in the strategy she put in place to “revitalise and refresh” the Danish firm’s pipeline upon taking the role three years ago. Following two recent acquisitions, Lundbeck now has a much broader focus across neuroscience including areas for…

Denmark Industry veteran Patrik Forsell oversees Takeda’s operations in Denmark. Here, Forsell talks through how sizeable shifts in the company’s global portfolio and focus over the past four years have played out at the Danish level, the increasingly challenging market access situation for rare disease treatments in the country, and how…

Denmark Tore von Würden talks through Amgen Denmark’s focus areas of osteoporosis, cardiovascular disease, haematology, and oncology, where it hopes not only to provide medicines but also contribute to the overall ecosystem. von Würden also explains the logic and relevance of the company’s M&A activity in Denmark in recent years, highlights…